サンプル依頼リスト カート
  • English
  • Korean
表紙：先端巨大症の世界市場レポート 2024年
市場調査レポート
商品コード
1415660

先端巨大症の世界市場レポート 2024年

Acromegaly Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
先端巨大症の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

先端巨大症の市場規模は近年急速に拡大しています。2023年の17億9,000万米ドルから2024年には21億5,000万米ドルに、CAGR19.8％で拡大します。歴史的な期間の成長は、先端巨大症治療薬の有病率の増加、先端巨大症に対する意識の高まり、政府の取り組み、効果的な治療に対する需要に起因しています。

先端巨大症市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR18.1％で41億7,000万米ドルに成長します。予測期間の成長は、先端巨大症治療法の研究開発活動への投資、スクリーニングプログラムの増加、ヘルスケア支出の増加、低侵襲治療オプションへの需要の増加に起因しています。予測期間における主な動向には、先端巨大症の革新的治療、先端巨大症の標的療法の開発、強力な医薬品パイプライン、治療オプションの進歩、高度個別化医療などが含まれます。

糖尿病を含むホルモン性疾患の罹患率の増加は、先端巨大症市場の成長を予測可能な将来に牽引するものと思われます。ホルモン疾患は内分泌疾患としても知られ、内分泌系の機能不全に起因する病状を包含します。糖尿病は、最も広範で影響力のあるホルモン疾患の1つです。先端巨大症は、他の内分泌疾患と並んで、成長ホルモンやコルチゾールなどの特定のホルモンが過剰に分泌された結果である可能性があります。例えば、2021年12月現在、米国を拠点とする政府間組織である国際糖尿病連合（International Diabetes Federation）のデータによると、2021年には20～79歳の成人5億3,700万人が糖尿病に罹患していることが明らかになっています。予測によると、この数は2030年までに約6億4300万人にまでエスカレートし、2045年には7億8300万人という驚異的な数に達すると予想されています。このように、ホルモン疾患の有病率の増加が先端巨大症市場の成長の原動力となっています。

遺伝子異常の有病率の上昇は、先端巨大症市場の将来的な拡大の主要な促進要因になると考えられています。遺伝子異常は、しばしば遺伝子欠陥や遺伝子障害として知られ、個人の遺伝子のDNA配列に現れる変化や突然変異を包含し、非典型的な特徴、機能、特性をもたらす可能性があります。下垂体による成長ホルモン（GH）の過剰産生を特徴とする疾患である先端巨大症は、非がん性腺腫と関連することが多く、これは散発的に発生することもあれば、特定の遺伝子異常と関連することもあります。例えば、2022年2月現在、スイスに本部を置く政府間機関である世界保健機関（WHO）のデータによると、先天性異常は毎年、生後28日以内に24万人の新生児の死亡に寄与しています。さらに、1カ月から5歳までの17万人の子供が、心臓病、神経管欠損症、ダウン症などの先天異常によって命を落としています。その結果、遺伝子異常の発生率が上昇しており、先端巨大症市場を前進させる準備が整っています。

2023年の先端巨大症市場では北米が最大地域でした。先端巨大症レポートがカバーしている地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の先端巨大症市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 異所性先端巨大症
  • 成長ホルモンによる先端巨大症
  • 世界の先端巨大症市場、診断別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • GHおよびIGF-Iの測定
  • 成長ホルモン抑制検査
  • イメージング
  • その他
  • 世界の先端巨大症市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • その他
  • 世界の先端巨大症市場、治療別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 薬
  • ソマトスタチン類似体
  • ドーパミンアゴニスト
  • 成長ホルモン拮抗薬
  • 手術
  • 放射線
  • その他の治療法
  • 世界の先端巨大症市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • 在宅ケア
  • その他

第7章 地域および国の分析

  • 世界の先端巨大症市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の先端巨大症市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 先端巨大症市場の競合情勢
  • 先端巨大症市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Private Limited
    • Merck &Co Inc.
    • AbbVie Inc.
    • Bayer AG

第31章 その他の主要および革新的な企業

  • Novartis AG
  • Sanofi S.A.
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Boehringer Ingelheim International GmbH.
  • Amgen Inc.
  • Allergan Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Ipsen Pharma S.A.
  • Hikma Pharmaceuticals PLC
  • Lupin Ltd.
  • Recordati S.p.A.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12259

“Acromegaly Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acromegaly market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acromegaly? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The acromegaly market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Ectopic Acromegaly; Acromegaly Due To Growth Hormone
  • 2) By Diagnosis: GH And IGF-I Measurement; Growth Hormone Suppression Test; Imaging; Other Diagnosis
  • 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
  • 4) By Treatment: Medication; Somatostatin analogues; Dopamine Agonists; Growth Hormone Antagonist; Surgery; Radiation; Other Treatments
  • 5) By End Users: Hospitals; Specialty Clinics; Homecare; Other End Users
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; Merck & Co Inc.; AbbVie Inc.; Bayer AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Acromegaly is an infrequent hormonal disorder stemming from the excessive production of growth hormone by the pituitary gland, a small structure situated at the base of the brain. This surplus of growth hormone triggers the enlargement and thickening of bones and tissues, predominantly affecting areas such as the hands, feet, and face.

The primary classifications of acromegaly encompass ectopic acromegaly and acromegaly due to growth hormone. Ectopic acromegaly is a rare medical condition characterized by the overproduction of growth hormone (GH) originating from a source outside the pituitary gland. The diagnostic methods employed include GH and IGF-I measurement, growth hormone suppression tests, imaging, and various others, which can be administered through diverse routes, including oral, parenteral, and others. Treatment options are available, ranging from medications, somatostatin analogues, dopamine agonists, and growth hormone antagonists to surgical procedures, radiation therapy, and other approaches. These treatments find application across various end users, including hospitals, specialty clinics, homecare settings, and others.

The acromegaly market research report is one of a series of new reports from The Business Research Company that provides acromegaly market statistics, including acromegaly industry global market size, regional shares, competitors with an acromegaly market share, detailed acromegaly market segments, market trends and opportunities and any further data you may need to thrive in the acromegaly industry. This acromegaly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acromegaly market size has grown rapidly in recent years. It will grow from $1.79 billion in 2023 to $2.15 billion in 2024 at a compound annual growth rate (CAGR) of 19.8%. The growth in the historic period can be attributed to increasing prevalence of acromegaly therapeutics, growing awareness about acromegaly, government initiatives, demand for effective treatments.

The acromegaly market size is expected to see rapid growth in the next few years. It will grow to $4.17 billion in 2028 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to investments in research and development activities for acromegaly treatments, growing number of screening programs, rising healthcare spending, increasing demand for minimally invasive treatment options. Major trends in the forecast period include innovative treatments for acromegaly, development of targeted therapies for acromegaly, strong pipeline of drugs, advancements in treatment options, advanced personalized medicine.

The increasing incidence of hormonal diseases, including diabetes, is set to drive the growth of the acromegaly market in the foreseeable future. Hormonal diseases, also known as endocrine disorders, encompass medical conditions arising from the malfunction of the endocrine system. Diabetes stands as one of the most widespread and impactful hormonal diseases. Acromegaly, alongside other endocrine disorders, can be a consequence of the excessive production of specific hormones, such as growth hormone or cortisol. Furthermore, owing to the profound effect of elevated growth hormone levels on insulin synthesis, approximately 50% of individuals with acromegaly may develop insulin resistance or type 2 diabetes mellitus.For example, as of December 2021, data from the International Diabetes Federation, a US-based intergovernmental organization, revealed that diabetes affected 537 million adults aged 20-79 years in 2021. Projections indicate that this number will escalate to approximately 643 million individuals by 2030 and is expected to reach a staggering total of 783 million by 2045. Thus, the increasing prevalence of hormonal diseases is the driving force behind the growth of the acromegaly market.

The escalating prevalence of genetic abnormalities is poised to be a key driver for the future expansion of the acromegaly market. Genetic abnormalities, often known as genetic defects or genetic disorders, encompass alterations or mutations that manifest in the DNA sequence of an individual's genes and can lead to atypical features, functions, or characteristics. Acromegaly, a condition characterized by the overproduction of growth hormone (GH) by the pituitary gland, is frequently associated with noncancerous adenomas, which can occur sporadically or be linked to specific genetic abnormalities. For instance, as of February 2022, data from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, indicated that congenital abnormalities contribute to the mortality of 240,000 newborns within the first 28 days of life annually. Additionally, an extra 170,000 children aged between 1 month and 5 years lose their lives due to congenital abnormalities, encompassing conditions like heart defects, neural tube defects, and Down syndrome. Consequently, the rising incidence of genetic abnormalities is poised to propel the acromegaly market forward.

The growth of the acromegaly market during the projected period is hampered by delayed diagnosis. The shortage of skilled healthcare professionals, particularly oncologists, poses a significant challenge for individuals afflicted with acromegaly. This dearth can result in delays in both diagnosis and treatment, elevating the risk of complications, and ultimately leading to diminished patient satisfaction. For instance, data from Frontiers Media SA in 2022 indicated that a substantial 22.6% of individuals dealing with acromegaly reported enduring a delay in their diagnosis. This delay often meant that more than a year elapsed between their initial medical consultation and the formal diagnosis of the condition. Consequently, delayed diagnosis remains a critical impediment to the growth of the acromegaly market.

The prominent companies in the acromegaly market are strategically focused on the development of inventive products and solutions to establish a competitive edge and maintain their market dominance. For example, in July 2021, Advanz Pharma Corp., a pharmaceutical company based in the United Kingdom, introduced Mytolac (lanreotide) in Germany. This marked the launch of the first generic lanreotide for the treatment of acromegaly, particularly for grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumors. Lanreotide comes highly recommended for addressing acromegaly patients whose levels of circulating growth hormone (GH) and insulin-like growth factor-1 (IGF-1) remain abnormal even after undergoing surgery, radiation therapy, or other medical interventions. This strategic emphasis on innovation underscores how inventive solutions are propelling these companies to establish their dominance in the acromegaly treatment market.

In September 2021, Xeris Pharmaceuticals Inc., a pharmaceutical company based in the United States, completed the acquisition of Strongbridge Biopharma PLC for an undisclosed sum. This strategic move culminated in the amalgamation of Xeris and Strongbridge's operations, forming a new entity known as Xeris Biopharma Holdings. The merged entity, Xeris, is poised to become a pioneering force in the fields of endocrinology and neurology. It boasts a unique technology platform ideally positioned to address the unmet needs of the patients it serves. Strongbridge Biopharma PLC, a biopharmaceutical company based in the United States, had been dedicated to the development of pharmaceuticals designed to treat rare endocrine disorders, with a particular focus on conditions like acromegaly.

Major players in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

North America was the largest region in the acromegaly market in 2023. The regions covered in acromegaly report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acromegaly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The acromegaly market consists of revenues earned by entities by providing hormone replacement therapy, pituitary radiotherapy and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The acromegaly market also includes sales of octreotide, lanreotide and somavert. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Acromegaly Market Characteristics

3. Acromegaly Market Trends And Strategies

4. Acromegaly Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Acromegaly Market Size and Growth

  • 5.1. Global Acromegaly Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Acromegaly Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Acromegaly Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Acromegaly Market Segmentation

  • 6.1. Global Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Ectopic Acromegaly
  • Acromegaly Due To Growth Hormone
  • 6.2. Global Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • GH And IGF-I Measurement
  • Growth Hormone Suppression Test
  • Imaging
  • Other Diagnosis
  • 6.3. Global Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Other Route Of Administrations
  • 6.4. Global Acromegaly Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Medication
  • Somatostatin analogues
  • Dopamine Agonists
  • Growth Hormone Antagonist
  • Surgery
  • Radiation
  • Other Treatments
  • 6.5. Global Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End Users

7. Acromegaly Market Regional And Country Analysis

  • 7.1. Global Acromegaly Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Acromegaly Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Acromegaly Market

  • 8.1. Asia-Pacific Acromegaly Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Acromegaly Market

  • 9.1. China Acromegaly Market Overview
  • 9.2. China Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Acromegaly Market

  • 10.1. India Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Acromegaly Market

  • 11.1. Japan Acromegaly Market Overview
  • 11.2. Japan Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Acromegaly Market

  • 12.1. Australia Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Acromegaly Market

  • 13.1. Indonesia Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Acromegaly Market

  • 14.1. South Korea Acromegaly Market Overview
  • 14.2. South Korea Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Acromegaly Market

  • 15.1. Western Europe Acromegaly Market Overview
  • 15.2. Western Europe Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Acromegaly Market

  • 16.1. UK Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Acromegaly Market

  • 17.1. Germany Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Acromegaly Market

  • 18.1. France Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Acromegaly Market

  • 19.1. Italy Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Acromegaly Market

  • 20.1. Spain Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Acromegaly Market

  • 21.1. Eastern Europe Acromegaly Market Overview
  • 21.2. Eastern Europe Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Acromegaly Market

  • 22.1. Russia Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Acromegaly Market

  • 23.1. North America Acromegaly Market Overview
  • 23.2. North America Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Acromegaly Market

  • 24.1. USA Acromegaly Market Overview
  • 24.2. USA Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Acromegaly Market

  • 25.1. Canada Acromegaly Market Overview
  • 25.2. Canada Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Acromegaly Market

  • 26.1. South America Acromegaly Market Overview
  • 26.2. South America Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Acromegaly Market

  • 27.1. Brazil Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Acromegaly Market

  • 28.1. Middle East Acromegaly Market Overview
  • 28.2. Middle East Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Acromegaly Market

  • 29.1. Africa Acromegaly Market Overview
  • 29.2. Africa Acromegaly Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Acromegaly Market Competitive Landscape And Company Profiles

  • 30.1. Acromegaly Market Competitive Landscape
  • 30.2. Acromegaly Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Private Limited
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bayer AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Acromegaly Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi S.A.
  • 31.3. AstraZeneca plc
  • 31.4. GlaxoSmithKline plc
  • 31.5. Eli Lilly and Company
  • 31.6. Gilead Sciences Inc.
  • 31.7. Boehringer Ingelheim International GmbH.
  • 31.8. Amgen Inc.
  • 31.9. Allergan Inc.
  • 31.10. Teva Pharmaceutical Industries Ltd.
  • 31.11. Mylan N.V.
  • 31.12. Ipsen Pharma S.A.
  • 31.13. Hikma Pharmaceuticals PLC
  • 31.14. Lupin Ltd.
  • 31.15. Recordati S.p.A.

32. Global Acromegaly Market Competitive Benchmarking

33. Global Acromegaly Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Acromegaly Market

35. Acromegaly Market Future Outlook and Potential Analysis

  • 35.1 Acromegaly Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Acromegaly Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Acromegaly Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer